Caffeine-Loaded Niosomes: Characterization and in Vitro Release Studies

Khazaeli, Payam; Pardakhty, Abbas; Shoorabi, Hamideh

doi:10.1080/10717540701603597

Cited by 71 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug release occurred in two phases, an initial fast release that lasted for 3-6 h, followed by a sustained, but reduced, slow release that was maintained at least for 72 h (Figure 4). This release pattern was in agreement with that reported in previous works 30,32,67,74,83 . The biphasic release pattern might be due to size heterogeneity of the vesicles 84 .…”

Section: In Vitro Release Profile Studies Of Nys Niosomessupporting

confidence: 94%

“…This might be due to disproportionate distribution of DCP or SA in the bilayers, which may increase the curvature of the bilayer through the effect on electrostatic repulsion between the ionized head group, thus increasing the hydrophilic surface area. This effect will result in smaller vesicles 14,60,67,[73][74][75][76][77][78] . On the contrary, inclusion of DCP or SA in the niosomal formulations of the molar ratio NIS/CHOL/CIA (2:1:0.25) F 5 , F 6 , F 11 and F 12 , respectively, increased the vesicle size compared with neutral vesicles, F 4 and F 10 .…”

Section: Effect Of Nis Structurementioning

confidence: 99%

See 1 more Smart Citation

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

El-Ridy

Abdelbary

Essam

et al. 2011

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Nonionic surfactant (NIS) vesicles (niosomes) formed from self-assembly of hydrated synthetic NIS monomers are capable of entrapping a variety of drugs and have been evaluated as an alternative to liposomes. Nystatin (NYS) is a polyene antifungal drug that has been used in the treatment of cutaneous, vaginal and oral fungal infections since the 1950s. The aim of this work is to encapsulate NYS in niosomes to obtain a safe and effective formula administered parenterally for neutropenic patients. NYS niosomes were prepared by the thin-film hydration method using Span 60 or Span 40 and cholesterol (CHOL). Stearylamine and dicetyl phosphate were added as the positive and negative charge-inducing agents (CIA), respectively. Two molar ratios were used, namely NIS/CHOL/CIA (1:1:0.1 and 2:1:0.25). Neutral and positively charged niosomes gave the highest encapsulation efficiencies. NYS niosomes were characterized using transmission electron microscopy, differential scanning calorimetry and dynamic light scattering. The release of neutral and negatively charged NYS niosomes was estimated, and it showed a slow sustained release profile. A 25-kGy γ-irradiation dose was sufficient to sterilize the investigated vesicles. NYS niosomes exerted less nephrotoxicity and hepatotoxicity in vivo, showed higher level of drug in vital organs and revealed pronounced efficacy in elimination of the fungal burden in experimental animals infected with Candida albicans compared with those treated with free NYS. Niosomal encapsulation thus provided means for parenteral administration of NYS, reducing its toxicity and making it a more active antifungal agent.

show abstract

Section: In Vitro Release Profile Studies Of Nys Niosomessupporting

confidence: 94%

Section: Effect Of Nis Structurementioning

confidence: 99%

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

El-Ridy

Abdelbary

Essam

et al. 2011

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

show abstract

“…These results were probably related to an almost negligible drug adsorption on the vesicle surface (Table 1), in agreement with data reported in the literature (39). The EE was rather low, in comparison to other vesicular formulations (39)(40) and was not influenced by the different molecular properties (Table 1) and, for this reason, release studies were carried out on non purified samples. Only the entrapment of NR was relevant, due to its high lipophilicity.…”

Section: Discussionsupporting

confidence: 80%

A New Vesicle-loaded Hydrogel System Suitable for Topical Applications: Preparation and Characterization

Carafa

Marianecci

Marzio³

et al. 2011

J Pharm Pharm Sci

View full text Add to dashboard Cite

-Purpose. Aim of this research was to prepare and study drug release from a new formulation consisting of non ionic surfactant vesicular structures, niosomes (NSVs), loaded with model molecules calcein (CALC), nile red (NR), ibuprofen (IBU) or caffeine (CAFF), and embedded in a hydrogel matrix. Methods. The system locust bean gum/xanthan (1:1), prepared at 60 °C, was used to entrap the vesicles (Tween 20/cholesterol 1:1), loaded with guest molecules and the release profiles were detected at 32 °C. The hydrogel systems were characterized by means of scanning electron microscopy; niosomes were characterized by means of size and -potential measurements. Results. Size measurements showed that a slight increase in vesicle dimensions occurs after inclusion of CALC or CAFF (hydrophilic molecules) in the vesicular structures. -potential measurements showed that the inclusion of these molecules did not significantly modify the surface charge of empty vesicles. This was probably related to an almost negligible drug adsorption on the vesicle surface. The release from the niosomes-gel systems of two probes (CALC and NR) showed that the diffusion of CALC through the gel was not affected by the niosome entrapment while for NR, the presence of vesicles was crucial. The release profiles from niosomes-gel systems and from the hydrogel alone of model drugs, CAFF and IBU, showed an appreciable difference between the two drugs: the more hydrophilic CAFF was released much faster than IBU. In all release studies turbidity, dimension and -potential analyses indicated that the loaded niosomes were released by the hydrogel matrix without being damaged. Conclusions. The reported in vitro experiments show the capability of the novel formulation to combine the qualities of both chosen single systems, i.e. the niosomes and the polymeric network. The hydrogel shows a protective effect on vesicle integrity and leads to a slow release of the loaded model molecules from the polysaccharidic system.

show abstract

“…In these drugs, dissolution of the drug is the rate limiting step in the absorption process. To triumph over these obstacles, numbers of formulation approaches are reported including the use of surfactants (Allaboun et al, 2003;Balakrishnan et al, 2004;Chakraborty et al, 2009), lipids (Yeap et al, 2013), permeation enhancers (Burcin et al, 2010;Beg et al, 2011), formation of salt (Li et al, 2005;Serajuddin, 2007), co-crystallization (Shan & Zaworotko, 2008;Qiao et al, 2011;Chadha et al, 2012), solid dispersions (Serajuddin, 1999), inclusion complexes with cyclodextrins and modified cyclodextrins (Miyake et al, 2000;Veiga et al, 2000;Wang et al, 2000;Bannwart et al, 2001;Carrier et al, 2007;Gamsiz et al, 2010a,b;Gamsiz et al, 2011;Badr-Eldin et al, 2008;Kumar et al, 2013), nanosuspensions (Patravale et al, 2004), and colloidal vesicles like liposomes (Nazzal et al, 2002a;Manconi et al, 2013;Yang et al, 2013), and niosomes (Khazaeli et al, 2007;Bayindir & Yuksel, 2010;SezginBayindir et al, 2013;Jin et al, 2013) In modern years, self-nanoemulsifying drug delivery systems (SNEDDS) are the most popular and commercially feasible lipid-based formulation approach for improving oral bioavailability of poorly water soluble and lipophilic drugs (Pouton, 2006;Date, 2007;Shweta et al, 2011). SNEDDS are precisely defined as an isotropic multi-component drug delivery systems composed of a synthetic or natural oil, surfactant, and co-surfactant that have a unique ability of forming fine oil in water micro-or nano-emulsion upon mild agitation followed by dilutio...…”

Section: Introductionmentioning

confidence: 99%

Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits

Mohd¹,

Sanka²,

Bandi³

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

(2015) Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits, Drug Delivery, 22:4, 499-508, DOI: 10.3109/10717544.2013 Context: This study presents novel self-nanoemulsifying drug delivery system potential of oral delivering which leads poorly aqueous soluble drug glimepiride.Objective: The objective of this study was to prepare solid self-nanoemulsifying drug delivery system (S-SNEDDS) for the improved oral delivery of glimepiride and to evaluate its therapeutic efficacy in albino rabbits.Results and discussion: The droplet size analyses revealed a droplet size of less than 200 nm. The solid state characterization of S-SNEDDS by scanning electron microscopy (SEM), X-ray powder diffraction and differential scanning calorimetry (DSC) revealed the absence of crystalline glimepiride in the S-SNEDDS. The in vitro dissolution studies revealed that the significant improvement in glimepiride release characteristics. The effect of S-SNEDDS on therapeutic efficacy of glimepride was assessed in albino rabbits by monitoring blood glucose levels and compared with free drug suspension, L-SNEDDS. The S-SNEDDS showed significant (p50.05) increase in in vitro drug release and therapeutic efficacy as compared with free drug. Conclusion: This study demonstrated that S-SNEDDS is a promising novel drug delivery system of glimepride to enhance oral delivery.

show abstract

Caffeine-Loaded Niosomes: Characterization and in Vitro Release Studies

Cited by 71 publications

References 20 publications

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

A New Vesicle-loaded Hydrogel System Suitable for Topical Applications: Preparation and Characterization

Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits

Contact Info

Product

Resources

About